Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $33.94 which represents a slight increase of $0.64 or 1.92% from the prior close of $33.3. The stock opened at $33.54 and touched a low ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

Mid-cap Health Care company Exelixis has logged a -1.2% change today on a trading volume of 1,601,263. The average volume for ...

Trump’s presidency may bring uncertainty within the health care sector (NYSEARCA:IYH), but certain pockets of the industry could offer the fundamentals for investors to stay afloat. “We believe ...

SpringWorks Therapeutics shows strong growth with approved drugs and potential for more, making it a promising buy. Read my ...

The United States market has been flat over the last week but is up 24% over the past year, with earnings forecast to grow by 15% annually. In this context of robust growth expectations, identifying ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

Geron Corporation (NASDAQ:GERN) has a negative Return on Invested Capital (ROIC) of -68.21%, indicating challenges in ...

The global phosphoinositide 3-kinase inhibitor market is poised to witness significant growth, projected to expand at a robust CAGR of 5.61% during the forecast period from 2019 to 2026.